RUPALL DIN 02456478
Status: Marketed
Holder: MEDEXUS PHARMACEUTICALS INC.
Molecule: RUPATADINE (RUPATADINE FUMARATE)
Available to quote
Health Canada record
| Active ingredient(s) | RUPATADINE (RUPATADINE FUMARATE) 1 MG |
|---|---|
| Dosage form | Solution |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | R06AX28 RUPATADINE |
| Original market date | 20-Jan-2017 |
| Current status date | 02-Feb-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Medexus Pharmaceuticals Inc. — licence 101526, currently licensed, last inspection rating C (2026-02-19).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RUPATADINE (RUPATADINE FUMARATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02553155 | APO-RUPATADINE | APOTEX INC | Tablet | RUPATADINE (RUPATADINE FUMARATE) 10 MG | Marketed |
| 02552604 | PMS-RUPATADINE | PHARMASCIENCE INC | Tablet | RUPATADINE (RUPATADINE FUMARATE) 10 MG | Marketed |
| 02560119 | RIVA-RUPATADINE | LABORATOIRE RIVA INC. | Tablet | RUPATADINE (RUPATADINE FUMARATE) 10 MG | Marketed |
| 02456451 | RUPALL | MEDEXUS PHARMACEUTICALS INC. | Tablet | RUPATADINE (RUPATADINE FUMARATE) 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30035 | 2023-02-02 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 23717 | 2020-06-04 | New Drug Submission (NDS) | Administrative: Merger/Buy-out |
| 18290 | 2016-07-20 | New Drug Submission (NDS) |